XBIO Quote, Financials, Valuation and Earnings

Iovance Biotherapeutics, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of -135.28%. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1552.89%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 273.3%. Given that Xenetic Biosciences, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Iovance Biotherapeutics, Inc..

Xenetic Biosciences, Inc. has a beta of 2.398, which suggesting that the stock is 139.837% more volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.

Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Xenetic Biosciences, Inc. quarterly revenues are $1M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Xenetic Biosciences, Inc.'s net income of -$509.9K is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.31x versus 2.93x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

KalVista Pharmaceuticals, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of -361.39%. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.

Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1552.89%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 111.46%. Given that Xenetic Biosciences, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than KalVista Pharmaceuticals, Inc..

Xenetic Biosciences, Inc. has a beta of 2.398, which suggesting that the stock is 139.837% more volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.135, suggesting its less volatile than the S&P 500 by 113.476%.

Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Xenetic Biosciences, Inc. quarterly revenues are $1M, which are smaller than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. Xenetic Biosciences, Inc.'s net income of -$509.9K is higher than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.31x versus 50.86x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Solid Biosciences, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of --. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat Solid Biosciences, Inc.'s return on equity of -77.74%.

Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1552.89%. On the other hand Solid Biosciences, Inc. has an analysts' consensus of $15.17 which suggests that it could grow by 192.23%. Given that Xenetic Biosciences, Inc. has higher upside potential than Solid Biosciences, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Solid Biosciences, Inc..

Xenetic Biosciences, Inc. has a beta of 2.398, which suggesting that the stock is 139.837% more volatile than S&P 500. In comparison Solid Biosciences, Inc. has a beta of 2.975, suggesting its more volatile than the S&P 500 by 197.54%.

Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solid Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. Solid Biosciences, Inc. pays out -- of its earnings as a dividend.

Xenetic Biosciences, Inc. quarterly revenues are $1M, which are larger than Solid Biosciences, Inc. quarterly revenues of --. Xenetic Biosciences, Inc.'s net income of -$509.9K is higher than Solid Biosciences, Inc.'s net income of -$45.8M. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while Solid Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.31x versus 20.36x for Solid Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of 15.59%. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1552.89%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 19.08%. Given that Xenetic Biosciences, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Travere Therapeutics, Inc..

Xenetic Biosciences, Inc. has a beta of 2.398, which suggesting that the stock is 139.837% more volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.

Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

Xenetic Biosciences, Inc. quarterly revenues are $1M, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Xenetic Biosciences, Inc.'s net income of -$509.9K is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.31x versus 7.26x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.